STING agonists, including cGAMP analogs, show promise in cancer immunotherapy and as vaccine adjuvants, while small-molecule inhibitors of cGAS or STING, such as covalent STING inhibitors, demonstrate potential for treating autoimmune diseases (e.g., AGS) and other chronic inflammatory disorders. This evidence concerns the gene CGAS and Aicardi-Goutieres syndrome.